Hepatology News

BOSTON — A treatment trial that recruited individuals chronically infected with hepatitis C virus and provided no-cost medical care helped reduce the proportion of viremic individuals in a rural Appalachian county, data showed.

BOSTON — Treatment with sofosbuvir-based direct-acting antivirals demonstrated durable sustained virologic response up to 5 years among pediatric patients with hepatitis C virus, according to findings presented at The Liver Meeting.

BOSTON — After 52 weeks, elafibranor achieved biochemical response and improved symptoms of pruritus in patients with primary biliary cholangitis, according to late-breaking data presented at The Liver Meeting.

BOSTON — Treatment with aldafermin 3 mg appeared to be well-tolerated and significantly reduced Enhance Liver Fibrosis score after 48 weeks among patients with metabolic dysfunction-associated steatohepatitis, according to a presenter.

BOSTON — In the absence of cirrhosis, no specific precautions are needed for patients with SARS-CoV-2 infection and a history of hepatitis C virus, according to findings presented at The Liver Meeting.

BOSTON — Female adolescents and young adults have higher rates of liver-related mortality and a 50% higher risk for cirrhosis and decompensation after surviving their first presentation of alcoholic hepatitis, according to data.

Topline findings from an extension of the phase 2b ENLIVEN trial showed that pegozafermin sustained improvements in fibrosis and disease resolution for patients with nonalcoholic steatohepatitis at 48 weeks, 89bio announced.

BOSTON — After 12 weeks of treatment with sofosbuvir/velpatasvir in combination with tenofovir alafenamide, patients with hepatitis C virus and hepatitis B virus co-infection demonstrated high rates of sustained virologic response.

BOSTON — Healio spoke with James L. Boyer, MD, about phase 3 findings from the RESPONSE trial and the ELATIVE trial and presented at The Liver Meeting.

BOSTON — Treatment with efruxifermin resulted in “clinically meaningful” but not yet statistically significant benefit at 36 weeks in cirrhotic patients with metabolic dysfunction-associated steatohepatitis, according to late-breaking data.